HCA
AMRX icon

Harbor Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Harbor Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
1,242
-71
-5% -$973 ﹤0.01% 841
2026
Q1 		$16K Sell
1,313
-347
-21% -$4.66K ﹤0.01% 874
2025
Q4 		$21K Sell
1,660
-28
-2% -$320 ﹤0.01% 813
2025
Q3 		$17K Buy
+1,688
New +$15.2K ﹤0.01% 831

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Harbor Capital Advisors's AMRX Position: Q2 2026 in Review

Harbor Capital Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 5.4% in Q2 2026, selling an estimated $973 and leaving 1,242 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #841.

Harbor Capital Advisors first reported a position in AMRX in Q3 2025 and has held it in 4 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Harbor Capital Advisors held 1,242 shares of Amneal Pharmaceuticals worth $21K as of Q2 2026.
  • Harbor Capital Advisors sold 71 Amneal Pharmaceuticals shares in Q2 2026, an estimated $973.
  • Amneal Pharmaceuticals made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #841 holding.
  • Harbor Capital Advisors first reported a position in Amneal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.